Ladostigil hemitartrate

Modify Date: 2024-01-11 10:09:34

Ladostigil hemitartrate Structure
Ladostigil hemitartrate structure
Common Name Ladostigil hemitartrate
CAS Number 209394-46-7 Molecular Weight 694.77
Density N/A Boiling Point 412.4ºC at 760 mmHg
Molecular Formula C16H20N2O2.1/2C4H6O6 Melting Point N/A
MSDS N/A Flash Point 203.2ºC

 Use of Ladostigil hemitartrate


Ladostigil (TV-3326) hemitartrate is a dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with an IC50 of 37.1 and 31.8 μM for MAO-B and AChE, reapectively. Ladostigil hemitartrate could increase cholinergic transmission, prevent the formation of ROS or their actions and be used for the research of depression and Alzheimer's disease[1][2].

 Names

Name (2R,3R)-2,3-dihydroxybutanedioic acid,[(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
Synonym More Synonyms

 Ladostigil hemitartrate Biological Activity

Description Ladostigil (TV-3326) hemitartrate is a dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with an IC50 of 37.1 and 31.8 μM for MAO-B and AChE, reapectively. Ladostigil hemitartrate could increase cholinergic transmission, prevent the formation of ROS or their actions and be used for the research of depression and Alzheimer's disease[1][2].
Related Catalog
Target

MAO-B:37.1 nM (IC50)

AChE:31.8 nM (IC50)

In Vitro Ladostigil (1-10 µM) hemitartrate exerts neuroprotective activities, including a prevention of the fall of the mitochondrial membrane potential (ψ), attenuation of apoptotic cascades and an inhibition of ROS production induced by OS insults[2]. Ladostigil (1-10 µM) hemitartrate has a significant neuroprotective activity, including inhibition of caspase-3 activation, induction of Bcl-2 and reduction of Bad and Bax gene and protein expression in human neuroblastoma SK-N-SH cells[2].
In Vivo Ladostigil (17 mg/kg; p.o. daily for 6 weeks) hemitartrate abolishes their hyperanxiety and depressive-like behaviour in the elevated plus maze (EPM) and forced swim tests (FST) tests in adulthood from puberty to prenatally-stressed rats[4]. Ladostigil (50 μmol/kg; single p.o.) hemitartrate restores the loss of episodic memory in the object recognition test in rats[3]. Animal Model: Pathogen-free (SPF) Sprague-Dawley rats[4] Dosage: 17 mg/kg Administration: P.o. (added to the drinking water) daily for 6 weeks Result: Inhibited brain MAO-A and B by more than 60%. Reduced hyperanxiety of male and female prenatally stressed (PS) rats in the EPM and depressive-like behaviour in the FST.
References

[1]. Denya I, et, al. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease. Medchemcomm. 2018 Jan 16;9(2):357-370.

[2]. Weinreb O, et, al. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.

[3]. Weinstock M, et, al. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J Neural Transm Suppl. 2006;(70):443-6.

[4]. Poltyrev T, et, al. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology (Berl). 2005 Aug;181(1):118-25.

 Chemical & Physical Properties

Boiling Point 412.4ºC at 760 mmHg
Molecular Formula C16H20N2O2.1/2C4H6O6
Molecular Weight 694.77
Flash Point 203.2ºC
Exact Mass 694.321411
PSA 198.20000
LogP 3.35360
Vapour Pressure 5.19E-07mmHg at 25°C

 Safety Information

Hazard Codes Xi

 Synthetic Route

~87%

Ladostigil hemitartrate Structure

Ladostigil hemi...

CAS#:209394-46-7

Literature: Aronhime, Judith; Bahar, Eliezer; Frenkel, Anton; Gottesfeld, Ronen; Gold, Amir; Koltai, Tamas Patent: US2007/88082 A1, 2007 ; Location in patent: Page/Page column 13 ;

 Precursor & DownStream

Precursor  2

DownStream  0

 Synonyms

ethyl-methyl-carbamic acid (R)-3-prop-2-ynylamino-indan-5-yl ester tartrate
TV-3326
Ladostigil tartrate
(3R)-3-(prop-2-ynylamino)-2,3,-dihydro-1H-indan-5-yl ethyl methyl carbamate tartrate
[(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
R(+)-6-(N-methyl-N-ethylcarbamoyloxy)-N'-propargyl-1-aminoindan tartrate
UNII-2J1346C51H
(2R,3R)-2,3-dihydroxybutanedioic acid
ethylmethylcarbamic acid (3R)-2,3-dihydro-3-(2-propynylamino)-1H-inden-5-yl ester (2R,3R)-2,3-dihydroxybutanedioate
R(+)-6-(N-methyl-N-ethylcarbamoyloxy)-N'-propargyl-1-aminoindan L-tartrate
TV-3219
(2R,3R)-2,3-Dihydroxysuccinic acid - (3R)-3-(2-propyn-1-ylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate (1:2)